CEMIP and cancer: Moreover, CEMIP promotes all 3 branches of the Wnt signaling pathways by modulating Ca2 + signaling via interacting with the cell-membrane receptor Ephrin A2, WW domain binding protein 11 (WBP11), Protein tyrosine phosphatase type IVA member 3 (PTP4A3) or ER receptor inositol 1,4,5-trisphosphate receptor type 2 (ITPR2).[12,13] Furthermore, the survival rate of solid cytoplasmic expression of CEMIP is one-quarter lower than that of nucleus strong expression at 4 years postoperatively.[5] The nuclear confinement status of CEMIP illustrates the relative safety of cancer patients.